{"id":"cladribine-cyclophosphamide-cytarabine-daunorubicin-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Hemorrhage"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cladribine and cytarabine are nucleoside analogs that inhibit DNA synthesis in leukemic blasts. Cyclophosphamide is an alkylating agent that cross-links DNA. Daunorubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II. Dexamethasone is a corticosteroid that enhances the cytotoxic effects and reduces inflammation. Together, these agents target leukemic cells through multiple mechanisms of DNA damage and cell death.","oneSentence":"This is a multi-drug chemotherapy regimen that combines nucleoside analogs, alkylating agents, and anthracyclines to kill rapidly dividing leukemic cells through DNA damage and inhibition of DNA synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:15.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute leukemia in pediatric patients"}]},"trialDetails":[{"nctId":"NCT00198991","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)","status":"COMPLETED","sponsor":"Goethe University","startDate":"2003-04","conditions":"Adult Acute Lymphocytic Leukemia","enrollment":1883},{"nctId":"NCT00136084","phase":"PHASE3","title":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2002-08","conditions":"Leukemia, Myelocytic, Acute","enrollment":238},{"nctId":"NCT00199017","phase":"PHASE4","title":"German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2004-04","conditions":"Lymphoma, Lymphoblastic","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone","genericName":"Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone","companyName":"St. Jude Children's Research Hospital","companyId":"st-jude-children-s-research-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a multi-drug chemotherapy regimen that combines nucleoside analogs, alkylating agents, and anthracyclines to kill rapidly dividing leukemic cells through DNA damage and inhibition of DNA synthesis. Used for Acute leukemia in pediatric patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}